These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 29018988)
21. Chromogranin A and the endothelial barrier function. Corti A; Ferrero E Curr Med Chem; 2012; 19(24):4051-8. PubMed ID: 22834794 [TBL] [Abstract][Full Text] [Related]
22. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results]. Glinicki P; Jeske W Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814 [TBL] [Abstract][Full Text] [Related]
23. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181 [TBL] [Abstract][Full Text] [Related]
24. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100 [TBL] [Abstract][Full Text] [Related]
25. Chromogranin A in gastrinomas: Promises and pitfalls. Rehfeld JF Clin Chim Acta; 2015 Jun; 446():15-20. PubMed ID: 25861845 [TBL] [Abstract][Full Text] [Related]
26. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis. Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865 [TBL] [Abstract][Full Text] [Related]
27. Decreased plasma Chromogranin A361-372 (Catestatin) but not Chromogranin A17-38 (Vasostatin) in female dogs with bacterial uterine infection (pyometra). Jitpean S; Stridsberg M; Pettersson A; Höglund OV; Holst BS; Hagman R BMC Vet Res; 2015 Jan; 11():14. PubMed ID: 25636335 [TBL] [Abstract][Full Text] [Related]
28. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954 [TBL] [Abstract][Full Text] [Related]
29. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report. Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828 [TBL] [Abstract][Full Text] [Related]
30. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011 [TBL] [Abstract][Full Text] [Related]
31. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors]. Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832 [TBL] [Abstract][Full Text] [Related]
32. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257 [TBL] [Abstract][Full Text] [Related]
33. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Kim M; Lee S; Lee J; Park SH; Park JO; Park YS; Kang WK; Kim ST Cancer Res Treat; 2016 Jan; 48(1):153-61. PubMed ID: 25779359 [TBL] [Abstract][Full Text] [Related]
34. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213 [TBL] [Abstract][Full Text] [Related]
35. Chromogranin A as biomarker in diabetes. Broedbaek K; Hilsted L Biomark Med; 2016 Nov; 10(11):1181-1189. PubMed ID: 27611656 [TBL] [Abstract][Full Text] [Related]
36. Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies. Tartaglia A; Portela-Gomes GM; Oberg K; Vezzadini P; Foschini MP; Stridsberg M Virchows Arch; 2006 Apr; 448(4):399-406. PubMed ID: 16408221 [TBL] [Abstract][Full Text] [Related]
37. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094 [TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254 [TBL] [Abstract][Full Text] [Related]
39. Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. Bachetti T; Ferrari Bardile A; Aloi TL; Colombo B; Assi E; Savino G; Vercelli A; Colombo R; Corti A Int J Cardiol; 2017 Jun; 236():438-443. PubMed ID: 28190616 [TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. Yang X; Yang Y; Li Z; Cheng C; Yang T; Wang C; Liu L; Liu S PLoS One; 2015; 10(4):e0124884. PubMed ID: 25894842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]